Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RADIATION THERAPY Cause Malignant neoplasm progression? 28 Reports in FDA Database

Prostate Health & Male Vitality — Naturally

ProstaVive: better flow, better sleep, better energy. 180-day guarantee.

Learn More

According to the FDA Adverse Event Reporting System (FAERS), 28 reports of Malignant neoplasm progression have been filed in association with RADIATION THERAPY. This represents 2.2% of all adverse event reports for RADIATION THERAPY.

28
Reports of Malignant neoplasm progression with RADIATION THERAPY
2.2%
of all RADIATION THERAPY reports
14
Deaths
10
Hospitalizations

How Dangerous Is Malignant neoplasm progression From RADIATION THERAPY?

Of the 28 reports, 14 (50.0%) resulted in death, 10 (35.7%) required hospitalization, and 1 (3.6%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RADIATION THERAPY. However, 28 reports have been filed with the FAERS database.

What Other Side Effects Does RADIATION THERAPY Cause?

Hot flush (226) Fatigue (195) Injection site pain (103) Asthenia (97) Diarrhoea (76) Nausea (75) Dysuria (63) Weight decreased (55) Vomiting (54) Weight increased (50)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which RADIATION THERAPY Alternatives Have Lower Malignant neoplasm progression Risk?

RADIATION THERAPY vs RADIUM RA-223 DICHLORIDE RADIATION THERAPY vs RALOXIFENE RADIATION THERAPY vs RALTEGRAVIR RADIATION THERAPY vs RALTITREXED RADIATION THERAPY vs RAMELTEON

Related Pages

RADIATION THERAPY Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression RADIATION THERAPY Demographics